Sep 10, 2020 9:15 am EDT Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Aug 25, 2020 9:15 am EDT Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
Aug 06, 2020 4:01 pm EDT Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Jul 30, 2020 9:15 am EDT Capricor Therapeutics to Present Second Quarter 2020 Financial Results and Recent Corporate Update on August 6
May 26, 2020 9:25 am EDT Capricor to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020
May 14, 2020 4:01 pm EDT Capricor Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020 4:30 pm EDT Capricor Therapeutics to Present First Quarter 2020 Financial Results and Recent Corporate Update on May 14
May 13, 2020 7:00 am EDT Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002